Patents by Inventor David Andrew Widdick

David Andrew Widdick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Twin-Arginine Translocation (TAT) Streptomyces Signal Sequences
    Publication number: 20090221038
    Abstract: Described herein are novel Tat signal polypeptides and methods for using the Tat signal polypeptides for producing heterologous polypeptides. A novel reporter assay for testing the biological activity of the secreted proteins is also described.
    Type: Application
    Filed: December 20, 2006
    Publication date: September 3, 2009
    Inventors: Tracy Palmer, David Andrew Widdick
  • Production of the lantibiotic cinnamycin with genes isolated from
    Patent number: 7166468
    Abstract: A 17 kb nucleic acid fragment, which confers production of the lantibiotic cinnamycin on non-producer Streptomycete strains, has been isolated from Streptomyces cinnamoneus cinnamoneus DSM 40005 and characterized. Also provided are variants of the 17 kb fragment including variants in which non-essential genes are deleted and variants in which the propeptide sequence of the cinnamycin structural gene is altered, for example replaced with the propeptide sequence of similar B-type lantibiotics. Also provided are vectors, host cells and methods of lantibiotic production using the nucleic acid of the invention, and libraries of variants.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: January 23, 2007
    Assignee: Plant Bioscience Limited
    Inventors: Mervyn James Bibb, David Andrew Widdick
  • Production of the lantibiotic cinnamycin with genes isolated from streptomyces cinnamoneus
    Publication number: 20040101963
    Abstract: A 17 kb nucleic acid fragment, which confers production of the lantihiotic cinnamycin on non-producer Strepto-mycete strains, has been isolated from Streptomyces cinnamoneus cinnamoneus DSM 40005 and characterised. Also provided are variants of the 17 kb fragment including variants in which non-essential genes are deleted and variants in which the propeptide sequence of the cinnamycin structural gene is altered, for example replaced with the propeptide sequence of similar B-type lantibiotics. Also provided are vectors, host cells and methods of lantibiotic production using the nucleic acid of the invention, and libraries of variants.
    Type: Application
    Filed: October 27, 2003
    Publication date: May 27, 2004
    Inventors: Mervyn James Bibb, David Andrew Widdick